Articles by Daniel Marsh
Meiwu Technology Surges 88% in Premarket After Steep Decline
Meiwu Technology shares rebounded 88% in premarket trading Tuesday after a sharp drop Monday. The company recently raised $15.65 million for an AI skincare platform.
Standard Chartered to Cut 7,000 Jobs, Target 18% Return by 2030
Standard Chartered announces 7,000 job cuts by 2030, targeting 18% RoTE, as it uses AI and automation to streamline operations. Record Q1 results support the plan.
SAP Shares Surge on AI Optimism and Positive Analyst Ratings
SAP SE shares jumped 5.8% on Tuesday, buoyed by AI-related announcements and favorable analyst coverage, though the stock remains down 25% for the year.
Virax Biolabs Stock Extends Surge on RedChip Promo, Filing
Virax Biolabs shares surged 53.1% Monday and climbed another 17.1% premarket Tuesday, driven by a paid RedChip TV segment and a May 15 ownership filing showing Armistice Capital's 4.99% stake.
Amesite Stock Surges on Largest NurseMagic Contract
Amesite Inc. shares surged 218% in premarket trading after securing its largest NurseMagic deployment with a 2,700-patient home-care client, though the company still faces financial uncertainty.
GeoVax Shares Surge on Biodefense Funding and Ebola Alert
GeoVax Labs shares surged nearly 80% after announcing a $3 million private placement, riding a wave of biodefense interest sparked by WHO's Ebola emergency in Africa.
Evolution AB Launches €2B Buyback, Shares Surge 9%
Evolution AB shares surged 9% in Stockholm after announcing a €2 billion share buyback, one of Sweden's largest. The program starts immediately and may run until the 2027 annual meeting.
T1 Energy Shares Jump on Institutional Filing, Solar Plans in Focus
T1 Energy shares surged 23% after a regulatory filing showed Situational Awareness LP held 10 million shares. The solar maker's Q1 revenue of $177.6M and on-schedule Austin plant fuel momentum.
Warner Bros. Discovery Stock Trades Below Intrinsic Value Amid Merger Speculation
Warner Bros. Discovery shares trade at $27.10, roughly 10% below some intrinsic value estimates but above a cited fair value of $18.17. Analysts remain divided amid merger talks with Paramount and regulatory uncertainty.
